GastrointestinalIn Clinical Trials

Peptide YY (PYY 3-36)

Intravenous, Intranasal

Overview

Peptide YY 3-36 is a 34-amino acid endogenous peptide hormone secreted by L-cells in the distal small intestine and colon in response to nutrient intake. It acts primarily on the Y2 receptor in the hypothalamus to reduce appetite and slow gastric emptying, functioning as part of the ileal brake mechanism.

Mechanism of Action

The therapeutic rationale for exogenous PYY 3-36 administration centers on treatment of obesity through appetite suppression. Circulating levels are reduced in obesity and elevated after bariatric surgery..

Research Summary & Key Findings

Early proof-of-concept studies demonstrated that intravenous PYY 3-36 infusion reduced food intake in both lean and obese subjects. Clinical development of intranasal formulations has been pursued to improve delivery, but phase II trials showed modest weight loss and challenges with patient adherence and tolerability. No PYY-based therapeutic has advanced beyond mid-stage trials, though interest persists in combination approaches with other gut hormones.

Clinical Status

In Clinical Trials

Peptide YY (PYY 3-36) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

IntravenousIntranasal

Related Peptides in Gastrointestinal

Find a Provider

Find a verified provider who offers Peptide YY (PYY 3-36) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Peptide YY (PYY 3-36).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.